MS and Demyelinating Disorders

Robert Zivadinov, MD, PhD, provided insight on the different components that need to be addressed to help stop—and potentially reverse—neurodegeneration in MS.

Here's what is coming soon to NeurologyLive.

The associate professor of Physical Medicine & Rehabilitation and nonclinical research psychologist at University of Michigan Medicine discussed the complexities of fatigue as a symptom following her presentation at CMCS 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 12, 2021.

The founder and CEO of Joi Wellness Group Multiple Sclerosis Center described motivations behind the evaluation of ocrelizumab (Ocrevus; Genentech) in minority populations with multiple sclerosis.

Outlining the development of the CHIMES trial in multiple sclerosis, the founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center spoke on tactics to get underrepresented populations involved. [WATCH TIME: 2 minutes]

A multiple sclerosis expert gives insight on which types of investigational agents may be able to repair neurodegeneration lost from disease progression.

The founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center outlined the motivations behind the trial, as well as potential reasons for underrepresentation. [WATCH TIME: 2 minutes]

Robert Zivadinov, MD, PhD, provides thoughts on hurdles of conducting clinical trials that incorporate imaging techniques sensitive and specific to myelin for patients with multiple sclerosis.

The chief of the Multiple Sclerosis Division, Perelman School of Medicine at the University of Pennsylvania emphasized current recommendations, which suggest patients with MS get vaccinated for COVID-19. [WATCH TIME: 3 minutes]

An multiple sclerosis expert shares his thoughts on enhancing myelin regeneration and repair to counteract neurodegeneration in patients with multiple sclerosis.

Marisa McGinley, DO, offered her perspective on the use of telemedicine in the management of patients with MS, summarizing the benefits it provides and the challenges that remain as it is more increasingly incorporated into care.

The professor of neurology at the NYU Grossman School of Medicine provided his thoughts on the most notable strides within the multiple sclerosis field in the past year. [WATCH TIME: 3 minutes]

The director of the Multiple Sclerosis Achievement Center in Sacramento discussed 3-year data from an assessment of the program, outlining key findings and future research efforts. [WATCH TIME: 6 minutes]

Here's what is coming soon to NeurologyLive.

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic shared her perspective on the use of telemedicine in MS care, what challenges it can address, and the need to optimize its use. [WATCH TIME: 6 minutes]

The chief of the Multiple Sclerosis Division at the Perelman School of Medicine, University of Pennsylvania, discussed recommendations for COVID-19 vaccination in this patient population, specifically for those on disease-modifying therapies. [WATCH TIME: 2 minutes]

Mona Bostick, RDN, LDN, MSCS, gave her perspective on nutrition in MS, popular elimination diets, and the role registered dietitians can play in the multidisciplinary care model.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 5, 2021.

The director of the Multiple Sclerosis Achievement Center outlined the design of the wellness programs, which are held in 2 different formats. [WATCH TIME: 4 minutes]

Expert clinicians offer their perspectives on the ongoing shortage of neurologists, stigmas associated with migraine, diets for those with epilepsy, mesenchymal stem cells in MS, and other topics.

Robert Fox, MD, discussed what’s currently available in terms of cannabis-derived medications that treat symptoms of multiple sclerosis, and realistic possibility of another soon entering the market.

Repeated analyses using both 3-mm and 1-mm diameter macular data—narrower volumes than standard—showed no relevant outer plexiform layer or outer nuclear layer thinning in those with seropositive AQP4-IgG.

Amit Bar-Or, MD, FRCPC, FAAN, FANA, commented on his presentations at CMSC 2021, one of which focused on COVID-19 vaccination, which experts do not believe poses risks for those on disease-modifying therapies.

The staff member at the Mellen Center for Multiple Sclerosis discussed reasons why patients may stop treatment, as well as strategies for maintaining communication with the healthcare team in the event of discontinuation. [WATCH TIME: 5 minutes]

An expert provided thoughts on the state of multiple sclerosis research, where the efforts have been directed recently, and areas that need increased focus.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

Brian Hutchinson, PT, MSCS, commented on the Multiple Sclerosis Achievement Center program, which includes patient data spanning a 3-year period.

The associate professor of pediatrics and neurology at Rutgers–Robert Wood Johnson Medical School commented on the need to recognize when adolescent patients are ready to learn more about their condition. [WATCH TIME: 5 minutes]